Outcomes in Chemotherapy-Ineligible Elderly Patients with Newly Diagnosed Acute Myeloid Leukemia Treated with Venetoclax Plus Azacitidine: A Pooled Analysis

被引：1
|
作者：
Venditti, Adriano [1 ]
Hou, Jing-Zhou [2 ]
Fenaux, Pierre [3 ]
Jonas, Brian A. [4 ]
Vrhovac, Radovan [5 ,6 ]
Montesinos, Pau [7 ]
Garcia, Jacqueline S. [8 ]
Rizzieri, David [9 ]
Thirman, Michael J. [10 ]
Kotey, Stanley [11 ]
Potluri, Jalaja [11 ]
Dhalla, Mazaher [11 ]
Pullarkat, Vinod [12 ]
机构：
[1] Univ Roma Tor Vergata, Dept Biomed & Prevent, Rome, Italy
[2] UPMC Hillman Canc Ctr, Lemieux Ctr Blood Canc, Hematol & BMT, Pittsburgh, PA USA
[3] Univ Paris, St Louis Hosp, Dept Hematol, Paris, France
[4] Univ Calif Davis, Div Malignant Hematol Cellular Therapy & Transpla, Dept Internal Med, Sch Med, Sacramento, CA USA
[5] Univ Hosp Ctr Zagreb, Dept Haematol, Zagreb, Croatia
[6] Univ Zagreb, Sch Med, Zagreb, Croatia
[7] Hosp Univ & Politecn La Fe, Valencia, Spain
[8] Harvard Med Sch, Dana Farber Canc Inst, Dept Med Oncol, Boston, MA USA
[9] Novant Hlth Canc Inst, Winston Salem, NC USA
[10] Univ Chicago, Sect Hematol Oncol, Dept Med, Chicago, IL USA
[11] AbbVie Inc, N Chicago, IL USA
[12] City Hope Comprehens Canc Ctr, Dept Hematol & Hematopoiet Cell Transplantat, Duarte, CA USA
来源：
BLOOD | 2023年 / 142卷
关键词：
D O I：
10.1182/blood-2023-182045
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
引用
收藏
页数：5
相关论文
共 50 条
  • [31] Hematologic improvements with ivosidenib plus azacitidine compared to placebo plus azacitidine in patients with newly diagnosed acute myeloid leukemia.
    Dohner, Hartmut
    Montesinos, Pau
    Polo, Susana Vives
    Zarzycka, Ewa
    Wang, Jianxiang
    Bertani, Giambattista
    Heuser, Michael
    Calado, Rodrigo T.
    Schuh, Andre C.
    Yeh, Su-Peng
    Burguera, Adolfo de la Fuente
    Cerchione, Claudio
    Daigle, Scott
    Hui, Jianan
    Pandya, Shuchi Sumant
    Gianolio, Diego A.
    Recher, Christian
    De Botton, Stephane
    JOURNAL OF CLINICAL ONCOLOGY, 2022, 40 (16)
  • [32] Safety and Efficacy of Azacitidine with Venetoclax for Newly Diagnosed Intensive Chemotherapy Ineligible, and Relapsed or Refractory Acute Myeloid Leukemia in Arab Population: A Single-Center, Retrospective Study
    Alwadi, Mohammmad
    Howaidi, Jude
    Alrajhi, Abdullah M.
    Alnakhli, Adel
    Marei, Mohammed A.
    Tailor, Imran K.
    Alnajjar, Fouad H.
    Altaf, Syed Y.
    Alnoamani, Mohammed S.
    Alzahrani, Kamal
    Alshehri, Hassan
    Motabi, Ibraheem H.
    Zaidi, Syed Ziauddin A.
    Alshehry, Nawal F.
    Alfayez, Mansour
    BLOOD, 2021, 138
  • [33] A Real World Study of Venetoclax Combined with Azacitidine in 64 Chinese Patients Newly Diagnosed Acute Myeloid Leukemia
    Qian, Jiejing
    Xu, Jieyu
    Hong, Qing
    Lou, Yinjun
    Mao, Liping
    Xu, Weilai
    Yang, Min
    Yu, Wenjuan
    Meng, Haitao
    Mai, Wenyuan
    Ye, Xiujing
    Zhu, Honghu
    Jin, Jie
    BLOOD, 2021, 138
  • [34] Venetoclax in Combination with Azacitidine for the Treatment of Newly Diagnosed Acute Myeloid Leukemia: A Canadian Cost-Utility Analysis
    Guinan, Kimberly
    Mathurin, Karine
    Au, Yunghan
    Schuh, Andre C.
    Bui, Cat N.
    Chai, Xinglei
    Lachaine, Jean
    CURRENT ONCOLOGY, 2022, 29 (10) : 7524 - 7536
  • [35] Outpatient Low-Dose Venetoclax Plus Azacitidine Vs. Intensive Chemotherapy for Newly Diagnosed Fit Patients with Acute Myeloid Leukemia in a Limited Resource Setting
    Lopez-Garcia, Yadith Karina
    De La Garza, Fernando
    De la Rosa-Flores, Gerardo Alexis
    Coronado Alejandro, Edgar Ulises
    Vega-Mateos, Antonio
    Tejada Vasquez, Ana Cristina
    Garcia-Salas, Gerardo
    Garcia-Zarate, Valeria
    Colunga-Pedraza, Perla R. Rocio
    Gomez-Almaguer, David
    Gomez-De Leon, Andres
    BLOOD, 2023, 142
  • [36] Venetoclax Combined with Homoharringtonine and Cytarabine (HAV) As Induction Treatment in Elder or Intensive Chemotherapy (IC) Ineligible Patients with Newly Diagnosed Acute Myeloid Leukemia
    Liu, Kaiqi
    Suo, Xiaohui
    Bai, Guanchen
    Yan, Zhangsong
    Li, Yang
    Zhang, Bin
    He, Jinsong
    Wei, Shuning
    Li, Qiuling
    Hu, Bo
    Mi, Yingchang
    BLOOD, 2023, 142
  • [37] A prospective study of all-trans retinoic acid plus venetoclax and azacitidine in newly diagnosed acute myeloid leukemia.
    Gu, Chengyuan
    Wang, Ruju
    Kang, Huizhu
    He, Xuefeng
    Chen, Jun
    Lin, Zhihong
    Liu, Yuejun
    Yang, Ting
    Wu, Depei
    Han, Yue
    JOURNAL OF CLINICAL ONCOLOGY, 2024, 42 (16)
  • [38] Management of Chemotherapy-Ineligible Acute Myeloid Leukemia: Beyond Hypomethylating Agent Monotherapy
    Stein, Eytan M.
    ONCOLOGY-NEW YORK, 2021, 35 (09): : 594 - 597
  • [39] Venetoclax plus daunorubicin and cytarabine in newly diagnosed acute myeloid leukemia patients: A propensity score-matched analysis
    Wang, Rong
    Zhang, Yi
    Chang, Jie
    Wang, Huafeng
    Lou, Yinjun
    Yang, Min
    Xu, Gaixiang
    Tong, Hongyan
    Xie, Wanzhuo
    Zhou, De
    Wei, Juying
    Mai, Wenyuan
    Ye, Xiujin
    Meng, Haitao
    Jin, Jie
    Zhu, Hong-Hu
    HEMATOLOGICAL ONCOLOGY, 2024, 42 (02)
  • [40] Retrospective, real-life study of venetoclax plus azacitidine or low-dose cytarabine in French patients with acute myeloid leukemia ineligible for intensive chemotherapy
    Laloi, Louise
    Billotey, Natacha Chaumard
    Dumas, Pierre-Yves
    Paul, Franciane
    Villate, Alban
    Simand, Celestine
    Fornecker, Luc
    Puisset, Florent
    Bertoli, Sarah
    Simonet, Marion Boissard
    Laribi, Kamel
    Houyou, Dyhia
    Santagostino, Alberto
    Michel, Claire
    Guepin, Gabrielle Roth
    Guerineau, Elodie
    Tabrizi, Reza
    Hunault, Mathilde
    Giltat, Aurelien
    Kaphan, Eleonore
    Bulabois, Claude
    Cartet, Elodie
    Rocher, Clement
    Lachenal, Florence
    Morisset, Stephane
    Recher, Christian
    Pigneux, Arnaud
    Belhabri, Amine
    Michallet, Mauricette
    Michallet, Anne-Sophie
    CANCER MEDICINE, 2023, 12 (06): : 7175 - 7181
12345